Werewolf Therapeutics (NASDAQ:HOWL) Earns Mkt Outperform Rating from Analysts at JMP Securities

JMP Securities initiated coverage on shares of Werewolf Therapeutics (NASDAQ:HOWL - Free Report) in a research report report published on Wednesday, MarketBeat.com reports. The firm issued a mkt outperform rating and a $12.00 price target on the stock.

Werewolf Therapeutics Stock Down 0.7 %

Shares of HOWL stock traded down $0.04 on Wednesday, hitting $6.02. The stock had a trading volume of 126,112 shares, compared to its average volume of 248,511. The business has a 50 day moving average of $6.24 and a 200 day moving average of $4.09. The stock has a market cap of $257.29 million, a price-to-earnings ratio of -5.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.29, a current ratio of 7.14 and a quick ratio of 7.14. Werewolf Therapeutics has a 12-month low of $1.57 and a 12-month high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.10. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative net margin of 187.37% and a negative return on equity of 32.25%. As a group, analysts expect that Werewolf Therapeutics will post -1.38 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in Werewolf Therapeutics by 25.8% during the second quarter. Renaissance Technologies LLC now owns 42,900 shares of the company's stock worth $131,000 after buying an additional 8,800 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Werewolf Therapeutics during the third quarter worth about $117,000. Rhumbline Advisers increased its holdings in Werewolf Therapeutics by 16.8% during the first quarter. Rhumbline Advisers now owns 22,550 shares of the company's stock worth $99,000 after buying an additional 3,245 shares during the last quarter. Northern Trust Corp increased its holdings in Werewolf Therapeutics by 31.0% during the second quarter. Northern Trust Corp now owns 26,067 shares of the company's stock worth $80,000 after buying an additional 6,161 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Werewolf Therapeutics during the fourth quarter worth about $79,000. Hedge funds and other institutional investors own 64.84% of the company's stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.